TE Connectivity plc Ordinary Shares vs State Street SPDR S&P Biotech ETF — how do they compare? TE Connectivity plc Ordinary Shares trades at $215.4 (market cap $62.05B), while State Street SPDR S&P Biotech ETF trades at $149.93 (market cap $10.11B). The key difference: TE Connectivity plc Ordinary Shares is far larger — about 6.1× State Street SPDR S&P Biotech ETF's market cap, and TE Connectivity plc Ordinary Shares pays a 1.46% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals.
| TEL | XBI | |
|---|---|---|
Market Cap | $62.05B | $10.11B |
Volume | 1,425,198 | 12,903,266 |
Sector | Technology | Broad Market / Factor |
52-Week High | $249.00 | $169.55 |
52-Week Low | $195.84 | $104.99 |
Enterprise Value | $66.44B | — |
Dividend Yield | 1.46% | — |
Typical Hold Time | — | 37 Days |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XBI trades at $150.23, down 0.44% on the day, with a bearish technical signal driven by moving averages and oscillators. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts. Recent news highlights sector optimism from cancer vaccine breakthroughs and improved capital access, though the ETF carries higher volatility than broader healthcare funds.
The outlook is mixed: strong sector tailwinds from innovation and consolidation support growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst sentiment is neutral with 100% hold ratings, suggesting cautious optimism amid technical bearishness.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
TE Connectivity designs and manufactures connectivity and sensor solutions. Its products support transportation, energy networks, industrial automation, communications infrastructure, and medical technology.
Read more on TEL →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →